Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth
What is the competitive landscape for Catalyst’s flagship products, and could competitor moves erode the recent growth?
How sensitive is CPRX's valuation to potential regulatory or reimbursement risks affecting the newly reported revenues?
Did the company allocate capital toward R&D, acquisitions, or share buybacks, and how will that affect its balance sheet?
20 days ago